How Ph.D. was paid
$1.7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Incentive | Other | Total |
|---|---|---|---|---|---|
| Yuichi Iwaki, M.D., Ph.D.President and Chief Executive Officer | $657,377 | $729,645 | $328,689 | $21,000 | $1,736,711 |
| Kazuko Matsuda, M.D., Ph.D., MPHSenior Vice President, Chief Medical Officer | $514,422 | $589,888 | $205,769 | $21,000 | $1,331,079 |
| David H. Crean, Ph.D.Chief Business Officer | $120,000 | — | — | — | $120,000 |
What changed and why
- $1.7MCEO total compensation increased to $1,736,711 in fiscal year 2025.
- 100%Performance-based stock options were granted in January 2025 and vested at 100% achievement.
- $10,000Dr. Crean served under a consulting agreement compensated at $10,000 per month.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.